We are live on ! Find out more
LPC

Lion Point Capital Portfolio holdings

AUM $16.7M
1-Year Est. Return 119.35%
This Fund
S&P 500
This Quarter Est. Return
+4.39%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$179M
AUM Growth
-$20.9M
Cap. Flow
-$34M
Cap. Flow %
-18.99%
Top 10 Hldgs %
92.09%
Holding
38
New
8
Increased
6
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
GERN icon
Geron
GERN
+$1.34M
2
MIST icon
Milestone Pharmaceuticals
MIST
+$1.06M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$1.02M
4
MLYS icon
Mineralys Therapeutics
MLYS
+$741K
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$680K

Top Sells

Rank Stock Value
1
SMTC icon
Semtech
SMTC
+$55.1M
2
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$2.6M
3
CBAY
Cymabay Therapeutics
CBAY
+$1.95M
4
BATL icon
Battalion Oil
BATL
+$1.41M
5
ARDX icon
Ardelyx
ARDX
+$898K

Sector Composition

Rank Sector Weight
1 Healthcare 16.67%
2 Consumer Discretionary 0.89%
3 Financials 0.47%
4 Energy 0.06%
5 Technology 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SMTC icon
1
CALL
Semtech
SMTC
$12.2B
$68.7M 38.4%
2,500,000
– –
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$81.5B
$52M 29.09%
247,500
+82,500
+50% +$16.5M
MRNS
3
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$19.2M 10.71%
2,119,136
-15,201
-0.7% -$148K
ARDX icon
4
Ardelyx
ARDX
$1.25B
$7.64M 4.27%
1,046,667
-105,000
-9% -$898K
XBI icon
5
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$4.74M 2.65%
+50,000
New +$4.64M
MIST icon
6
Milestone Pharmaceuticals
MIST
$146M
$4.12M 2.3%
2,300,207
+650,000
+39% +$1.06M
KNSA icon
7
Kiniksa Pharmaceuticals
KNSA
$4.83B
$2.58M 1.44%
130,691
– –
GERN icon
8
Geron
GERN
$924M
$1.98M 1.11%
+600,000
New +$1.34M
INSM icon
9
Insmed
INSM
$23.1B
$1.91M 1.07%
70,335
– –
FENC icon
10
Fennec Pharmaceuticals
FENC
$356M
$1.89M 1.06%
170,000
+60,000
+55% +$602K
BFI
11
DELISTED
BurgerFi International, Inc. Common Stock
BFI
$1.59M 0.89%
2,745,938
– –
SNDX icon
12
Syndax Pharmaceuticals
SNDX
$1.84B
$1.55M 0.86%
65,000
+30,500
+88% +$680K
AVDL
13
DELISTED
Avadel Pharmaceuticals
AVDL
$1.39M 0.78%
82,500
+2,500
+3% +$37.2K
MIRM icon
14
PUT
Mirum Pharmaceuticals
MIRM
$6.86B
$1.13M 0.63%
+45,000
New +$1.24M
BLUE
15
DELISTED
bluebird bio
BLUE
$1.09M 0.61%
42,413
+15,850
+60% +$406K
NBIX icon
16
Neurocrine Biosciences
NBIX
$17.7B
$1.03M 0.58%
+7,500
New +$1.02M
JSPR icon
17
Jasper Therapeutics
JSPR
$24.1M
$940K 0.53%
+32,000
New +$568K
NFYS
18
DELISTED
Enphys Acquisition Corp.
NFYS
$845K 0.47%
78,125
– –
MLYS icon
19
Mineralys Therapeutics
MLYS
$2.36B
$775K 0.43%
+60,000
New +$741K
HUMA icon
20
Humacyte
HUMA
$168M
$731K 0.41%
235,000
– –
RGNX icon
21
Regenxbio
RGNX
$622M
$685K 0.38%
+32,500
New +$578K
TVTX icon
22
Travere Therapeutics
TVTX
$5.31B
$601K 0.34%
78,000
– –
REPL icon
23
Replimune Group
REPL
$855M
$347K 0.19%
42,500
– –
MCRB icon
24
Seres Therapeutics
MCRB
$49.5M
$264K 0.15%
17,038
– –
LUMO
25
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$256K 0.14%
90,794
– –
1
2

Similar funds

PA
PPM America Chicago, Illinois $16.6M AUM 31.99% 1-Year Est. Return
PA
Prossimo Advisors San Luis Obispo, California $16.4M AUM 14% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
SRA
Summit Rock Advisors New York $16M AUM
CP
Covalent Partners Concord, Massachusetts $17.6M AUM 2.91% 1-Year Est. Return
B
BP London, United Kingdom $17.7M AUM 12.34% 1-Year Est. Return
CVV
Curative Ventures V Dallas, Texas $15.6M AUM 52.53% 1-Year Est. Return

Lion Point Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Lion Point Capital held 38 positions worth $179M, down 10% from $200M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Lion Point Capital withdrew a net $34M in Q1 2024, closing 6 positions and reducing 4 holdings. Its most notable exit was Harpoon Therapeutics, Inc. Common Stock, an estimated $2.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Lion Point Capital opened a new position in Geron worth $1.98M.

  • Lion Point Capital's largest Q1 2024 buy was Geron: 600,000 shares worth $1.98M.
  • Lion Point Capital added most to Milestone Pharmaceuticals in Q1 2024, an estimated $1.06M increase.
  • Lion Point Capital's biggest Q1 2024 reduction was Semtech, cutting an estimated $55.1M.
  • Lion Point Capital fully exited Harpoon Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $2.6M.
  • Lion Point Capital's ten largest holdings make up 92% of its $179M portfolio in Q1 2024.
  • Lion Point Capital opened 8 new positions and closed 6 in Q1 2024.
  • Lion Point Capital's portfolio value fell 10% quarter-over-quarter to $179M.

Based on Lion Point Capital's 13F filing for Q1 2024, filed 15 May 2024.